

A review of the evidence supporting the use of lithium augmentation therapy for the reduction of suicidal behavior in patients with unipolar depression: Revisiting an overlooked benefit of an older medication

Elizabeth Jackson, PharmD¹

Rene A. Endow-Eyer, PharmD, BCPP²

¹PGY-1 Pharmacy Resident, Veterans Affairs San Diego Healthcare System

²Psychiatric Clinical Pharmacist Specialist, Veterans Affairs San Diego Healthcare System

ABSTRACT

Major depressive disorder is a serious, recurrent condition with significant impact on a person's quality of life and functioning, which carries a significant risk of premature death due to suicide. There is evidence that supports the effectiveness of lithium as an augmentation strategy for treatment-resistant depression, as well as for reducing suicidality in this population. This review introduces several theories regarding the proposed mechanism behind lithium's anti-suicidal effects and summarizes a selection of the pertinent literature supporting lithium's beneficial effects on suicidality.

KEYWORDS

major depressive disorder (MDD), depression, lithium, suicide

INTRODUCTION

Major depressive disorder (MDD) is associated with significant morbidity and mortality. It has been estimated that the lifetime risk of suicide in patients with major depression approaches 15%, and approximately 50-70% of people who commit suicide have a documented diagnosis of depression.¹ Further complicating the issue is that depression is often refractory to pharmacologic treatment; less than 50% of patients respond to the first antidepressant trial, and only 33% achieve remission.² Response and remission rates decrease even further with each successive medication trial.³⁻⁴

The mainstay of pharmacologic treatment for MDD is antidepressant medication, with selective serotonin reuptake inhibitors (SSRIs) being the most commonly prescribed antidepressant class.⁵ While antidepressant agents have been shown to elicit both response and remission, there is no conclusive data that these medications affect suicidality.

The etiology of suicidal behavior is complex, thus it is recommended that a multifactorial approach must be taken in the management of suicidal patients.⁶ Several risk factors for suicide, both modifiable and non-modifiable, are listed in Table 1.

Although lithium was first described in the literature for the treatment of "psychotic excitement" in 1949 by John Cade,⁷ its mechanism of action is still not completely

understood. Studies in the 1970's and 1980's yielded convincing evidence that lithium augmentation reduces suicidal behavior and improves outcomes in patients with unipolar depression.⁸⁻¹¹ While lithium is still considered a mainstay of treatment for bipolar disorder, it is not commonly used for unipolar depression, despite the fact that there is evidence that lithium is effective as an augmentation strategy in major depression.

LITHIUM AND SUICIDE PREVENTION

There are several theories regarding the mechanism by which lithium reduces suicidality. Lithium has been shown to reduce recurrence of major depressive episodes when used as augmentation therapy along with antidepressant medication.^{8,10,12-20} However, studies have shown that lithium may have an anti-suicidal effect independent of its ability to reduce recurrence of depression.^{21,22} In a study of 167 high risk patients with a history of suicide attempt, it was shown that patients who responded to lithium treatment had a pronounced reduction in suicide attempts (93.3%).²¹ It was noted that > 80% of moderate responders and nearly 50% of poor responders had no further suicidal behavior after treatment with lithium. The results of this study suggest that lithium may still be able to reduce suicidality even if antidepressant response is not achieved with lithium augmentation therapy.

Another theory is that lithium decreases the risk of suicide by reducing aggression and impulsivity, a finding which has been shown in both human and animal studies.²²⁻²⁹

Table 1: Risk factors for suicide⁶

Modifiable	Potentially modifiable	Non-modifiable
Mental health disorders		
Substance use disorder	Major depressive disorder Bipolar disorder Schizophrenia/schizoaffective Anxiety disorders	
Social factors		
Relationship turbulence	Loss of health/autonomy	Loss of loved one
Family violence	Transitions in life	History of abuse
Poor social support	Anniversaries Financial stressors Legal issues Barriers to accessing mental health care	
Medical conditions		
Diabetes	Worsening of chronic illness Chronic pain Neurologic disorders Cancer	History of traumatic brain injury HIV
Pre-existing		
		Age (young or elderly) Gender (male) Race (Caucasian) Family history of suicide Family history of mental health disorder Same sex orientation Lower education level
Other		
	Impulsivity	History of suicide attempt

Additionally, lithium treatment may elicit a synergistic effect with antidepressants by enhancing serotonergic neurotransmission.³⁰ An added factor that may contribute to the decreased risk of suicide associated with lithium is the close follow-up associated with lithium treatment. It is conceivable that more frequent clinic visits and increased patient-provider interaction may reduce the risk of suicide and improve outcomes.³¹

Lithium's role in reducing suicidal behavior in depression is not a new consideration, as the first study addressing this concept was published in 1972.³² Since then, a considerable amount of literature has been published in support of this theory. A study by Ahrens et al. demonstrated that during the first two years of lithium treatment, suicide mortality remained high among patients with major affective disorders (including bipolar disorder and major depressive disorder), yet among those who had been treated with ≥ 2 years of lithium maintenance, mortality from both suicide and cardiovascular causes approximated that of the general population.³³ This finding was further substantiated by the results of a meta-analysis by Baldessarini et al., where

it was found that the risk for both suicide attempts and completions in patients with major affective disorders was initially 10 times that of the general population, but this risk fell below that of the general population with lithium maintenance treatment. The risk reduction was actually found to be higher in unipolar depression than bipolar depression (100% vs. 82%).³¹

A recent review by Cipriani et al., including 48 randomized controlled trials, showed that lithium was more effective than placebo in decreasing the number of suicides and deaths from any cause in patients with mood disorders, and specifically in individuals with unipolar depression (odds ratios: 0.36 and 0.13, respectively).³⁴ Guzzetta et al. found that the overall risk of suicide and suicide attempts was 88.5% lower with lithium versus without lithium augmentation in patients with major depressive disorder.³⁵ The International Group for the Study of Lithium-treated Patients (IGSLi), covering > 5,000 patient-years, also showed that adequate long-term lithium treatment significantly decreased excess mortality of patients with affective disorders down to the level of the general population.³⁶

SIDE EFFECTS AND ADVERSE DRUG REACTIONS

While the evidence appears to support the efficacy of lithium augmentation in the reduction of suicidal behavior in patients with depression, there are also factors that must be taken into consideration when making the decision to prescribe lithium. Potential adverse effects associated with lithium include hypothyroidism, tremor, acne, weight gain, gastrointestinal disturbances, cognitive impairment, electrocardiographic changes, and rarely nephrotoxicity.³⁷ However, it has been shown that many adverse effects may be avoided by maintaining lower, yet therapeutic, serum levels.³⁸ Furthermore, there is concern that lithium may be associated with Ebstein's anomaly, a congenital cardiovascular malformation, therefore clinicians may prefer to avoid this medication in women of child-bearing potential.³⁹ There are also several important drug interactions that must be considered when prescribing lithium. Most nonsteroidal anti-inflammatory drugs (NSAIDs) and several classes of antihypertensives, including angiotensin converting enzyme inhibitors (ACEIs) and thiazide diuretics, should be avoided as concomitant use may increase the risk of lithium toxicity.^{40,41} Additionally, rare case reports of serotonin syndrome following combination of lithium with other serotonergic agents, have been reported.⁴²⁻⁴⁴ Finally, serum lithium levels must be monitored when initiating therapy, changing lithium dose, and periodically during maintenance treatment, which raises pharmacoeconomic and adherence concerns.⁴⁵

DOSING AND SERUM LEVELS

A question that may arise when considering the use of lithium as augmentation for unipolar depression is that of dosing. There are no specific recommendations for the dosing of lithium as an adjunctive therapy in unipolar depression. In a study assessing the benefit of lithium added to a tricyclic antidepressant, serum concentrations ranged from 0.4-1.2 mEq/L; however, marked improvement in symptoms was observed at lithium concentrations of 0.4-0.5 mEq/L.⁴⁶ A study by Bauer et al. suggested that lithium exerts a significant effect at a dose of 600-800 mg/day and recommends target concentrations of 0.6-0.8 mEq/L.¹⁶ Coppen et al reported that a lithium trough level of 0.5-0.7 mEq/L was the most effective blood concentration. These levels were well-tolerated with only minor side effects.⁴⁷ Lepkifker et al reported a significant reduction in suicidal behavior with average lithium trough concentration of 0.4-0.8 mEq/L.²⁰ Thus the current evidence suggests that the target lithium trough levels for depression should be similar to those for lithium maintenance therapy in bipolar disorder.

The "ideal" serum lithium level for maintenance therapy in bipolar disorder is debated, but recent reviews and experts tend to agree that a serum concentration of 0.5-0.8mEq/L should be targeted to maximize efficacy while minimizing side effects.^{45,48}

TREATMENT GUIDELINES

Despite substantial evidence, there was no existing U.S. published guideline that specifically recommended the use of lithium for prevention of suicide as an augmentation agent in unipolar depression until recently. Although lithium had been added to the recommendations in the 2010 American Psychiatric Association (APA) Guideline for Major Depressive Disorder, and mentioned in the APA guideline for suicide prevention, prescribing rates of lithium for augmentation of depression have remained surprisingly low.⁴⁹ A study of 244,859 Veterans Affairs patients with a diagnosis of MDD and an antidepressant prescription reported that while 22% of patients received an augmenting agent, only 0.5% of patients received lithium.⁵⁰

The newly published 2013 Veterans Affairs – Department of Defense (VA-DoD) guideline for the Assessment and Management of Patients at Risk for Suicide recommends that "lithium augmentation should be considered for patients diagnosed with unipolar depressive disorder who have had a partial response to an antidepressant and for those with recurrent episodes who are at high risk for suicidal behavior, provided they do not have a contraindication to lithium use and the potential benefits outweigh the risks."⁶ These new recommendations may increase awareness of the efficacy of lithium in decreasing suicidality in unipolar depression.

CONCLUSION

Major depressive disorder is associated with a significant risk of premature death due to suicide. There is substantial evidence supporting lithium's specific anti-suicidal effect in both bipolar disorder and major depression. Despite such evidence, prescribing rates of lithium continue to decrease, likely due to concerns regarding side effects, monitoring, and lithium toxicity. Yet, suicide rates are increasing across all geographical locations in the United States.⁵¹ A study by Goodwin, et al highlights a haunting trend; in a population sample of over 20,000 outpatients with bipolar disorder followed over seven years it was shown that patients experienced a 2.7 times increased risk of suicide death while treated with divalproex compared to being treated with lithium.⁵² Additionally, it was noted that prescribing rates of lithium decreased dramatically over the time course of the study.

This was associated with a statistically insignificant, yet notable, increase in suicide rates over time. Hopefully, with increased awareness of the anti-suicidal effect of lithium, prescribers will be more inclined to use this medication to prevent suicide in patients with major affective disorders.

REFERENCES

- Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. *Br J Psychiatry*. 1997;170:205-28. PubMed PMID: [9229027](#).
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *Am J Psychiatry*. 2006;163(1):28-40. DOI: [10.1176/appi.ajp.163.1.28](#). PubMed PMID: [16390886](#).
- Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. *N Engl J Med*. 2006;354(12):1231-42. DOI: [10.1056/NEJMoa052963](#). PubMed PMID: [16554525](#).
- Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. *Am J Psychiatry*. 2006;163(7):1161-72. DOI: [10.1176/appi.ajp.163.7.1161](#). PubMed PMID: [16816220](#).
- Drayton SJ. Bipolar Disorder. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. *Pharmacotherapy: a pathophysiologic approach*. 8th ed New York, NY: McGraw-Hill; 2011:1191-1208.
- The Assessment and Management of Risk for Suicide Working Group (2013). *VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide*. Version 1.0. Washington, DC: Veterans Health Administration and Department of Defense.
- Cade JF. Lithium salts in the treatment of psychotic excitement. *Aust NZ J Psychiatry*. 1982;16(3):129-33. DOI: [10.3109/00048678209159969](#).
- Dé Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. *Br J Psychiatry*. 1981;138:252-6. PubMed PMID: [7272619](#).
- Coppen A, Noguera R, Bailey J, Burns BH, Swani MS, Hare EH, et al. Prophylactic lithium in affective disorders. Controlled trial. *Lancet*. 1974;2(7719):275-9. PubMed PMID: [4104974](#).
- Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. *Arch Gen Psychiatry*. 1983;40(12):1335-42. PubMed PMID: [6418110](#).
- Lepkifker E, Horesh N, Floru S. Long-term lithium prophylaxis in recurrent unipolar depression. A controversial indication? *Acta Psychiatr Belg*. 1985;85(3):434-43. PubMed PMID: [4050501](#).
- Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry*. 2000;157(9):1429-35. PubMed PMID: [10964859](#).
- Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. *Pharmacopsychiatry*. 1989;22(5):183-7. DOI: [10.1055/S-2007-1014603](#). PubMed PMID: [2682692](#).
- Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. *Br J Psychiatry*. 1995;166(1):80-6. PubMed PMID: [7894881](#).
- Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. *Can J Psychiatry*. 2003;48(7):440-8. PubMed PMID: [12971013](#).
- Bauer M, Forsthoef A, Baethge C, Adli M, Berghöfer A, Döpfmer S, et al. Lithium augmentation therapy in refractory depression-update 2002. *Eur Arch Psychiatry Clin Neurosci*. 2003;253(3):132-9. DOI: [10.1007/s00406-003-0430-9](#). PubMed PMID: [12904977](#).
- Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. *Pharmacopsychiatry*. 2001;34(4):19-27. DOI: [10.1055/S-2001-15873](#). PubMed PMID: [11518471](#).
- Fawcett JA. Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. *J Clin Psychiatry*. 2003;64 Suppl 5:32-7. PubMed PMID: [12720482](#).
- Köhler S, Unger T, Hoffmann S, Steinacher B, Fydrich T, Bschor T. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. *Pharmacopsychiatry*. 2013;46(2):69-76. DOI: [10.1055/S-0032-1323677](#). PubMed PMID: [23093475](#).
- Lepkifker E, Iancu I, Horesh N, Strous RD, Kotler M. Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation. *Depress Anxiety*. 2007;24(8):571-6. DOI: [10.1002/da.20273](#). PubMed PMID: [17133442](#).
- Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? *Pharmacopsychiatry*. 2001;34(4):132-6. DOI: [10.1055/S-2001-15878](#). PubMed PMID: [11518473](#).
- Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. *Neuropsychobiology*. 2010;62(1):43-9. DOI: [10.1159/000314309](#). PubMed PMID: [20453534](#).
- Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. *Am J Psychiatry*. 1976;133(12):1409-13. PubMed PMID: [984241](#).
- Wickham EA, Reed JV. Lithium for the control of aggressive and self-mutilating behaviour. *Int Clin Psychopharmacol*. 1987;2(3):181-90. PubMed PMID: [3320183](#).
- Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. *Arch Gen Psychiatry*. 2000;57(7):649-54. DOI: [10.1001/archpsyc.57.7.649](#).
- Comai S, Tau M, Pavlovic Z, Gobbi G. The psychopharmacology of aggressive behavior: a translational approach: part 2: clinical studies using atypical antipsychotics, anticonvulsants, and lithium. *J Clin Psychopharmacol*. 2012;32(2):237-60. DOI: [10.1097/JCP.0b013e31824929d6](#). PubMed PMID: [22367663](#).
- Siassi I. Lithium treatment of impulsive behavior in children. *J Clin Psychiatry*. 1982;43(12):482-4. PubMed PMID: [6819289](#).
- Halcomb ME, Gould TD, Grahame NJ. Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice. *Neuropsychopharmacology*. 2013;38(10):1937-44. DOI: [10.1038/npp.2013.89](#). PubMed PMID: [23584261](#).
- Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? *Am J Psychiatry*. 2005;162(1):137-45. DOI: [10.1176/appi.ajp.162.1.137](#). PubMed PMID: [15625212](#).
- Blier P, de Montigny C. Short-term lithium administration enhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS. *Eur J Pharmacol*. 1985;113(1):69-77. PubMed PMID: [2995061](#).
- Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. *J Clin Psychiatry*. 2003;64 Suppl 5:44-52. PubMed PMID: [12720484](#).
- Barraclough B, Bunch J, Nelson B, Sainsbury P. A hundred cases of suicide: clinical aspects. *Br J Psychiatry*. 1974;125:355-73. PubMed PMID: [4425774](#).
- Ahrens B, Grof P, Möller HJ, Müller-Oerlinghausen B, Wolf T. Extended survival of patients on long-term lithium treatment. *Can J Psychiatry*. 1995;40(5):241-6. PubMed PMID: [7535542](#).
- Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ*. 2013;346:f3646. DOI: [10.1136/bmj.f3646](#). PubMed PMID: [23814104](#).
- Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. *J Clin Psychiatry*. 2007;68(3):380-3. PubMed PMID: [17388706](#).
- Müller-Oerlinghausen B, Wolf T, Ahrens B, Schou M, Grof E, Grof P, et al. Mortality during initial and during later lithium treatment. A collaborative study by the International Group for the Study of Lithium-treated Patients. *Acta Psychiatr Scand*. 1994;90(4):295-7. PubMed PMID: [7832001](#).

37. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. *Lancet*. 2012;379(9817):721-8. DOI: [10.1016/S0140-6736\(11\)61516-X](https://doi.org/10.1016/S0140-6736(11)61516-X).
38. Schou M. Lithium prophylaxis: myths and realities. *Am J Psychiatry*. 1989;146(5):573-6. PubMed PMID: [2653052](https://pubmed.ncbi.nlm.nih.gov/2653052/).
39. Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. *Am J Psychiatry*. 1975;132(5):529-31. PubMed PMID: [1119612](https://pubmed.ncbi.nlm.nih.gov/1119612/).
40. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. *Clin Pharmacokinet*. 1995;29(3):172-91. DOI: [10.2165/00003088-199529030-00004](https://doi.org/10.2165/00003088-199529030-00004). PubMed PMID: [8521679](https://pubmed.ncbi.nlm.nih.gov/8521679/).
41. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. *J Clin Psychopharmacol*. 1990;10(5):350-4. PubMed PMID: [2258452](https://pubmed.ncbi.nlm.nih.gov/2258452/).
42. Adan-Manes J, Novalbos J, López-Rodríguez R, Ayuso-Mateos JL, Abad-Santos F. Lithium and venlafaxine interaction: a case of serotonin syndrome. *J Clin Pharm Ther*. 2006;31(4):397-400. DOI: [10.1111/j.1365-2710.2006.00745.x](https://doi.org/10.1111/j.1365-2710.2006.00745.x). PubMed PMID: [16882112](https://pubmed.ncbi.nlm.nih.gov/16882112/).
43. Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. *Am J Psychiatry*. 1993;150(10):1565. PubMed PMID: [8379573](https://pubmed.ncbi.nlm.nih.gov/8379573/).
44. Nisijima K, Shimizu M, Abe T, Ishiguro T. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. *Int Clin Psychopharmacol*. 1996;11(4):289-90. PubMed PMID: [9031998](https://pubmed.ncbi.nlm.nih.gov/9031998/).
45. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). *Am J Psychiatry*. 2002;159(Suppl 4):1-50.
46. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caillé G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. *Arch Gen Psychiatry*. 1983;40(12):1327-34. PubMed PMID: [6418109](https://pubmed.ncbi.nlm.nih.gov/6418109/).
47. Coppen A. Lithium in unipolar depression and the prevention of suicide. *J Clin Psychiatry*. 2000;61 Suppl 9:52-6. PubMed PMID: [10826662](https://pubmed.ncbi.nlm.nih.gov/10826662/).
48. Wijeratne C, Draper B. Reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity. *Aust N Z J Psychiatry*. 2011;45(12):1026-32. DOI: [10.3109/00048674.2011.610296](https://doi.org/10.3109/00048674.2011.610296). PubMed PMID: [21961481](https://pubmed.ncbi.nlm.nih.gov/21961481/).
49. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, third edition. *Am J Psychiatry*. 2010;167(suppl):1-152.
50. Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. *Am J Psychiatry*. 2006;163(7):1219-25. DOI: [10.1176/appi.ajp.163.7.1219](https://doi.org/10.1176/appi.ajp.163.7.1219). PubMed PMID: [16816227](https://pubmed.ncbi.nlm.nih.gov/16816227/).
51. Chakravarthy B, Frumin E, Lotfipour S. Increasing Suicide Rates Among Middle-age Persons and Interventions to Manage Patients with Psychiatric Complaints. *West J Emerg Med*. 2014;15(1):11-3. DOI: [10.5811/westjem.2013.12.19513](https://doi.org/10.5811/westjem.2013.12.19513). PubMed PMID: [24578763](https://pubmed.ncbi.nlm.nih.gov/24578763/); PubMed Central PMCID: [PMC3935781](https://pubmed.ncbi.nlm.nih.gov/PMC3935781/).
52. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. *JAMA*. 2003;290(11):1467-73. DOI: [10.1001/jama.290.11.1467](https://doi.org/10.1001/jama.290.11.1467). PubMed PMID: [13129986](https://pubmed.ncbi.nlm.nih.gov/13129986/).

How to cite this article

Jackson E, Endow-Eyer RA. A review of the evidence supporting the use of lithium augmentation therapy for the reduction of suicidal behavior in patients with unipolar depression: Revisiting an overlooked benefit of an older medication. *Ment Health Clin* [Internet]. 2014;4(5):221-5. Available from: <http://dx.doi.org/10.9740/mhc.n207175>